epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

Ann Allergy Asthma Immunol

ACAAI 2026: Could GLP-1 drugs help curb asthma flares?

November 20, 2026

card-image

Clinical takeaway: For overweight or obese patients with asthma, discuss potential asthma benefits when considering GLP-1 therapy for an established indication. Continue guideline-based asthma treatment since these observational findings do not support prescribing GLP-1 drugs specifically for asthma.

Obesity is associated with more frequent asthma exacerbations and poorer disease control. GLP-1 receptor agonists could potentially help improve asthma control through weight reduction and anti-inflammatory effects.

The review included five retrospective cohort studies involving more than 73,000 participants, according to an abstract published in Annals of Allergy, Asthma & Immunology. Pooled results from three obesity-specific cohorts linked GLP-1 therapy to a 27% lower risk of asthma exacerbations, with favorable associations also reported in adults without diabetes.

Among overweight or obese adolescents, treatment was associated with 58% lower risk of asthma-related emergency department visits and 34% fewer systemic corticosteroid prescriptions. A large obesity cohort also showed better asthma control, although exacerbation odds did not differ significantly.

Results varied substantially across the pooled studies, and risk of bias ranged from moderate to serious. Adverse-event reporting was insufficient to pool safety outcomes.

Researchers systematically searched medical databases, ClinicalTrials.gov, and major conference proceedings through June 2026 for comparative studies involving overweight or obese patients with asthma. Asthma exacerbations were the main outcome pooled in the meta-analysis with other outcome measures analyzed separately.

“Prospective randomized trials are needed to confirm these findings and further characterize safety,” the authors concluded.

Source: Bitar A, et al. (2026 Nov) Ann Allergy Asthma Immunol. Abstract A021. GLP-1 receptor agonists and asthma outcomes in patients with obesity: A systematic review and meta-analysis

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information